Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 4/20 | 0.57 |
| ▸ | TPH1 | P17752 | 1/20 | 0.49 |
| ▸ | CTSC | P53634 | 9/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.49 |
| ▸ | FAP | Q12884 | 2/20 | 0.49 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.49 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.49 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.49 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.49 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.49 |
| ▸ | MMP12 | P39900 | 1/20 | 0.48 |
| ▸ | MMP13 | P45452 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.43 |
| ▸ | MMP3 | P08254 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL289816 | 1.00 | DPP4 (0.57) | DPP4TPH1CTSCKCNH2FAP | |
| SCHEMBL8385357 | 0.95 | DPP4 (0.52) | DPP4TPH1CTSCKCNH2FAP | |
| SCHEMBL10266644 | 0.95 | DPP4 (0.52) | DPP4TPH1CTSCKCNH2FAP | |
| SCHEMBL8650928 | 0.95 | DPP4 (0.52) | DPP4TPH1CTSCKCNH2FAP | |
| SCHEMBL17060769 | 0.87 | TPH1 (0.61) | DPP4TPH1CTSCKCNH2FAP | |
| SCHEMBL14601776 | 0.87 | TPH1 (0.61) | DPP4TPH1CTSCKCNH2FAP | |
| SCHEMBL539320 | 0.82 | DPP4 (0.53) | DPP4TPH1CTSCKCNH2FAP | |
| SCHEMBL539319 | 0.82 | DPP4 (0.53) | DPP4TPH1CTSCKCNH2FAP | |
| SCHEMBL539309 | 0.82 | DPP4 (0.53) | DPP4TPH1CTSCKCNH2FAP | |
| SCHEMBL43594 | 0.81 | SLC7A5 (0.62) | DPP4TPH1KCNH2FAPDPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120329775-A1 | SUBSTITUTED 1-CYANOETHYLHETEROCYCLYLCARBOXAMIDE COMPOUNDS 750 | FORD RHONAN (GB) | 2012-12-27 | — | — | US | disclosed |
| US-20120329775-A1 | SUBSTITUTED 1-CYANOETHYLHETEROCYCLYLCARBOXAMIDE COMPOUNDS 750 | FORD RHONAN (GB) | 2012-12-27 | — | — | US | disclosed |
| US-8193239-B2 | Substituted 1-cyanoethylheterocyclylcarboxamide compounds | ASTRAZENECA AB (SE) | 2012-06-05 | — | — | US | disclosed |
| US-8193239-B2 | Substituted 1-cyanoethylheterocyclylcarboxamide compounds | ASTRAZENECA AB (SE) | 2012-06-05 | — | — | US | disclosed |
| US-8193239-B2 | Substituted 1-cyanoethylheterocyclylcarboxamide compounds | ASTRAZENECA AB (SE) | 2012-06-05 | — | — | US | disclosed |
| EP-2427445-A1 | SUBSTITUTED 1-CYANOETHYLHETEROCYCLYLCARBOXAMIDE COMPOUNDS 750 | AstraZeneca AB (SE) | 2012-03-14 | — | — | EP | disclosed |
| WO-2011154677-A1 | SUBSTITUTED N-[1-CYANO-2-(PHENYL)ETHYL] 1-AMINOCYCLOALK-1-YLCARBOXAMIDE COMPOUNDS - 760 | ASTRAZENECA AB (SE) | 2011-12-15 | — | — | WO | disclosed |
| WO-2011154677-A1 | SUBSTITUTED N-[1-CYANO-2-(PHENYL)ETHYL] 1-AMINOCYCLOALK-1-YLCARBOXAMIDE COMPOUNDS - 760 | ASTRAZENECA AB (SE) | 2011-12-15 | — | — | WO | disclosed |
| WO-2010128324-A1 | SUBSTITUTED 1-CYANOETHYLHETEROCYCLYLCARBOXAMIDE COMPOUNDS 750 | ASTRAZENECA AB (SE) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010128324-A1 | SUBSTITUTED 1-CYANOETHYLHETEROCYCLYLCARBOXAMIDE COMPOUNDS 750 | ASTRAZENECA AB (SE) | 2010-11-11 | — | — | WO | disclosed |
| US-20100286118-A1 | SUBSTITUTED 1-CYANOETHYLHETEROCYCLYLCARBOXAMIDE COMPOUNDS 750 | ASTRAZENECA AB (SE) | 2010-11-11 | — | — | US | disclosed |
| US-20100286118-A1 | SUBSTITUTED 1-CYANOETHYLHETEROCYCLYLCARBOXAMIDE COMPOUNDS 750 | ASTRAZENECA AB (SE) | 2010-11-11 | — | — | US | disclosed |
| US-20100286118-A1 | SUBSTITUTED 1-CYANOETHYLHETEROCYCLYLCARBOXAMIDE COMPOUNDS 750 | ASTRAZENECA AB (SE) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286118-A1 | SUBSTITUTED 1-CYANOETHYLHETEROCYCLYLCARBOXAMIDE COMPOUNDS 750 | CNR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CNR2 | DPP4 3367/4885TPH1 1546/4885CTSC 1989/4885 |
| US-20120329775-A1 | SUBSTITUTED 1-CYANOETHYLHETEROCYCLYLCARBOXAMIDE COMPOUNDS 750 | CNR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CNR2 | DPP4 3367/4885TPH1 1546/4885CTSC 1989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.